| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2023―Jul―18 |
Staying Ahead of the Game: How SARS-CoV-2 has Accelerated the Application of Machine Learning in Pandemic Management |
Alexander H. Williams, Chang-Guo Zhan |
| 2 |
[GO] |
2023―Mai―06 |
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy |
Francesco Ciccimarra, Nicoletta Luxi, Chiara Bellitto, Luca L’ Abbate, Pasquale De Nardo, Alessia Savoldi, et al. (+4) Alison Yeomans, Mariam Molokhia, Evelina Tacconelli, Gianluca Trifirò |
| 3 |
[GO] |
2022―Jun―28 |
Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (VigilVacCOVID Study) |
Joaquín Sáez-Peñataro, Ferran Torres, Joan Bartra, Juan Bascuas, Anna Vilella, Marta Tortajada, et al. (+37) Sebastiana Quesada, Elisenda González, Ester López-Suñé, Antoni Castells, Sandra Serrano, Concepción Camacho, Antoni Trilla, Gonzalo Calvo, Gonzalo Calvo, Joaquin Sáez-Peñataro, Concepción Camacho, Ferran Torres, Sandra Serrano, Joan Bartra, Antoni Trilla, Anna Vilella, Elisenda González, Marta Tortajada, Sebastiana Quesada, Antoni Castells, Maria-Jesús Bertran, Cristina Carrera, Maria Galisteo, Sara Gómez, Ester López-Suñé, Rosa Muñoz, Mariona Pascal, José Luis Pérez, Juan Bascuas, Luis Aparicio, Susanna Bañuelos, Pilar Cano, Vanessa de Dios, Anna Massó, Celia Puente, Carlos Sánchez, Martina Villarreal |
| 4 |
[GO] |
2022―Jun―13 |
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management |
Nicoletta Luxi, Alexia Giovanazzi, Alessandra Arcolaci, Patrizia Bonadonna, Maria Angiola Crivellaro, Paola Maria Cutroneo, et al. (+9) Carmen Ferrajolo, Fabiana Furci, Lucia Guidolin, Ugo Moretti, Elisa Olivieri, Giuliana Petrelli, Giovanna Zanoni, Gianenrico Senna, Gianluca Trifirò |
| 5 |
[GO] |
2022―Apr―27 |
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants |
William R. Strohl, Zhiqiang Ku, Zhiqiang An, Stephen F. Carroll, Bruce A. Keyt, Lila M. Strohl |
| 6 |
[GO] |
2021―Nov―29 |
SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin |
Andreas Volk, Caroline Covini-Souris, Denis Kuehnel, Christian De Mey, Jürgen Römisch, Torben Schmidt |
| 7 |
[GO] |
2020―Okt―13 |
Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour? |
Shubham Atal, Zeenat Fatima, Sadasivam Balakrishnan |
| 8 |
[GO] |
2020―Jun―17 |
Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks |
Salvatore Crisafulli, Valentina Isgrò, Laura La Corte, Fabiola Atzeni, Gianluca Trifirò |
|
